Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00FGR
|
|||
| Former ID |
DPR000076
|
|||
| Drug Name |
Miltefosine
|
|||
| Synonyms |
HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Leishmaniasis [ICD-11: 1F54; ICD-10: B55, B55.9] | Approved | [1] | |
| Visceral leishmaniasis [ICD-11: 1F54.0; ICD-10: B55.0; ICD-9: 85] | Phase 2 | [2] | ||
| Therapeutic Class |
Antifungal Agents
|
|||
| Company |
Aeterna Zentaris
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H46NO4P
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
|
|||
| InChI |
1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
|
|||
| InChIKey |
PQLXHQMOHUQAKB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 58066-85-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
226520, 484338, 4562729, 8137426, 8152270, 12014266, 14781695, 17396669, 26612907, 26680623, 26749044, 26749045, 26759174, 29222725, 49747674, 49748182, 49966181, 50107510, 53788176, 53800667, 57321887, 75270305, 91010630, 92124640, 92308871, 93620194, 103186893, 103942430, 104303974, 118846353, 124633439, 124633952, 124637845, 125334625, 126592939, 126645243, 126664051, 131319651, 134339527, 134358597, 135030585, 136946455, 137106670, 139786526, 144075829, 144116216, 144205019, 152054305, 162009789, 162173181
|
|||
| ChEBI ID |
CHEBI:75283
|
|||
| ADReCS Drug ID | BADD_D01469 | |||
| SuperDrug ATC ID |
L01XX09
|
|||
| SuperDrug CAS ID |
cas=058066856
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phospholipase A2 (PLA2G1B) | Target Info | Inhibitor | [2] |
| BioCyc | Phospholipases | |||
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Ether lipid metabolism | ||||
| Arachidonic acid metabolism | ||||
| Linoleic acid metabolism | ||||
| alpha-Linolenic acid metabolism | ||||
| Metabolic pathways | ||||
| Ras signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Pancreatic secretion | ||||
| Fat digestion and absorption | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| Reactome | Acyl chain remodelling of PC | |||
| Acyl chain remodelling of PE | ||||
| Acyl chain remodelling of PI | ||||
| WikiPathways | Glycerophospholipid biosynthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||
| REF 2 | Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.